ReviewHormones and behavior2013
Neuroprotection with non-feminizing estrogen analogues: an overlooked possible therapeutic strategy.
Review in Hormones and behavior, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A New Approach for Exploring Reperfusion Brain Damage in Hypoxic Ischemic Encephalopathy.Molecular neurobiology · 2024Article
- Neurosteroid enantiomers as potentially novel neurotherapeutics.Neuroscience and biobehavioral reviews · 2023Review
- 17β-estradiol (E2) in membranes: Orientation and dynamic properties.Biochimica et biophysica acta · 2016Article
- Cyclic Ozone Exposure Induces Gender-Dependent Neuropathology and Memory Decline in an Animal Model of Alzheimer's Disease.Toxicological sciences : an official journal of the Society of Toxicology · 2015Article
- Non-feminizing estrogens: a novel neuroprotective therapy.Molecular and cellular endocrinology · 2014Review
- Causes and consequences of age-related steroid hormone changes: insights gained from nonhuman primates.Journal of neuroendocrinology · 2013Review
- Glucocorticoid-dependent hippocampal transcriptome in male rats: pathway-specific alterations with aging.Endocrinology · 2013Article
- Estrogen regulation of Dkk1 and Wnt/β-Catenin signaling in neurodegenerative disease.Brain research · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Although many of the effects of estrogens on the brain are mediated through estrogen receptors (ERs), there is evidence that neuroprotective activity of estrogens can be mediated by non-ER mechanisms. Herein, we review the substantial evidence that estrogens neuroprotection is in large part non-ER mediated and describe in vitro and in vivo studies that support this conclusion. Also, we described our drug discovery strategy for capitalizing on enhancement in neuroprotection while at the same time, reducing ER binding of a group of synthetic non-feminizing estrogens. Finally, we offer evidence that part of the neuroprotection of these non-feminizing estrogens is due to enhancement in redox potential of the synthesized compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.